DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Data regarding the usefulness of percutaneous coronary intervention (PCI) with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR) in every day clinical practice is scarce. We aimed to evaluate comparing the efficacy and safety profile of DEB and thin-DES in DES-ISR.

See also
Status	Clinical Trial	Phase
Completed	`NCT04240444` - Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis	N/A
Not yet recruiting	`NCT04518826` - A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES
Completed	`NCT05112250` - IVL for Stent Underexpantsion
Completed	`NCT00485004` - Focal In-stent Restenosis After Drug-Eluting Stent	Phase 4

NCT number	NCT04415216
Study type	Observational [Patient Registry]
Source	Medical University of Silesia
Contact
Status	Completed
Phase
Start date	October 10, 2019
Completion date	March 1, 2020

DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry) — DEB-DRAGON

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms